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53BP1 is a chromatin-associated protein that regulates the DNA damage response. In this study, we identify the TPX2/Aurora 
A heterodimer, nominally considered a mitotic kinase complex, as a novel binding partner of 53BP1. We find that TPX2/Aurora 
A plays a previously unrecognized role in DNA damage repair and replication fork stability by counteracting 53BP1 function. 
Loss of TPX2 or Aurora A compromises DNA end resection, BRCA1 and Rad51 recruitment, and homologous recombination. 
Furthermore, loss of TPX2 or Aurora A causes deprotection of stalled replication forks upon replication stress induction. This 
fork protection pathway counteracts MRE11 nuclease activity but functions in parallel to BRCA1. Strikingly, concurrent loss 
of 53BP1 rescues not only BRCA1/Rad51 recruitment but also the fork instability induced upon TPX2 loss. Our work suggests 
the presence of a feedback mechanism by which 53BP1 is regulated by a novel binding partner and uncovers a unique role for 
53BP1 in replication fork stability.
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Introduction
DNA double-stranded breaks (DSBs) pose a substantial threat to 
genome integrity. Two primary mechanisms, nonhomologous 
end joining and homologous recombination (HR), repair DSBs 
(Chapman et al., 2012). HR is promoted by the tumor suppressor 
BRCA1, which recruits CtIP and Rad51, facilitating end resection 
and strand invasion of the sister chromatid. Conversely, 53BP1 
promotes nonhomologous end joining through its downstream 
effectors RIF1, PTIP, and the REV7-shieldin complex, which block 
DNA end resection and the recruitment of HR proteins (Callen et 
al., 2013; Feng et al., 2013; Noordermeer et al., 2018).
Recent studies using single-molecule DNA fiber assays show 
that another function of BRCA1 is to protect stalled replication 
forks from degradation by MRE11 (Schlacher et al., 2012). Loss of 
PTIP prevents MRE11 accumulation at stalled forks and rescues 
nascent DNA shortening in BRCA1-deficient cells, conferring 
chemoresistance despite sustaining defects in HR. This suggests 
that protection of the replication fork is a key mechanism by 
which BRCA-deficient cancers survive (Ray Chaudhuri et al., 
2016). Interestingly, unlike PTIP, loss of 53BP1 does not rescue 
shortened DNA tracks in BRCA1-deficient cells (Ray Chaudhuri et 
al., 2016). However, 53BP1 is enriched at stalled replication forks 
and forms nuclear bodies in G1 that sequester chromosomal le-
sions caused by replication stress during the previous cell cycle 
(Lukas et al., 2011; Dungrawala et al., 2015). Thus, although 53BP1 
is primed to function in response to replication stress, its role in 
this context is still unclear.
Here, through a proteomic interaction screen, we identify 
TPX2 as a direct 53BP1 interactor, which in turn recruits the 
Aurora A kinase. TPX2 and Aurora A canonically play critical 
roles in orchestrating mitotic spindle events (Neumayer et al., 
2014). Our work uncovers two novel nonmitotic functions of the 
TPX2/Aurora A heterodimer in regulating HR and replication 
fork stability and implicates a feedback mechanism modulating 
53BP1 function.
Results and discussion
To gain a better understanding of 53BP1 function, we stably ex-
pressed and purified 53BP1 from HeLa-S cells by tandem affin-
ity purification (TAP), as previously described (Nakatani and 
Ogryzko, 2003). Mass spectrometry (MS) analysis identified 
known 53BP1 interactors, including RIF1, MDC1, and USP28 
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(Fig. 1, A and B; and Table S1; Zimmermann and de Lange, 2014). 
By MS, we also copurified TPX2 and its kinase partner Aurora A, a 
heterodimer involved in mitotic progression and spindle assem-
bly (Fig. 1, A and B; Neumayer et al., 2014). Immunoprecipitation 
of endogenous TPX2 confirmed its association with 53BP1 with 
or without γ-irradiation (Fig. 1 C). Next, we demonstrated that 
recombinant 53BP1 and TPX2 physically interact by in vitro pull-
down assays (Figs. 1, D–H; and S1 A). Deletion analysis of 53BP1 
revealed that the TPX2-binding region overlaps with the Tudor 
and BRCT domains, which are critical for 53BP1 localization to 
chromatin (Fig. 1, D and E). We did not observe TPX2 recruit-
ment to sites of DNA damage induced by γ-irradiation or laser 
microirradiation (Fig. S1 B), suggesting that the interaction may 
occur primarily off the chromatin template. Furthermore, TPX2 
residues 150–394 were important for the interaction with 53BP1 
(Fig. 1, F–H). We next assessed the interaction between recombi-
nant 53BP1 and Aurora A and found that, unlike TPX2, 53BP1 does 
not directly bind to Aurora A in vitro (Fig. 1 I). However, upon 
the addition of recombinant TPX2, 53BP1 bound immobilized 
His-Aurora A. This interaction was significantly reduced when 
TPX2-Δ150-394 was substituted for WT TPX2 (Fig. 1 I), suggesting 
that TPX2 mediates the interaction between 53BP1 and Aurora A 
using this region. Using phosphorylation of histone H3 serine 
10 as a measure of Aurora A catalytic activity, we found that the 
TPX2-Δ150-394 53BP1-interaction mutant (hereafter referred 
to as TPX2-BP1-IM) activated Aurora A similarly to WT TPX2 in 
vitro, suggesting that this key mitotic function is maintained in 
this mutant protein (Fig. S1 C; Crosio et al., 2002).
Given that the TPX2 binding region on 53BP1 includes the 
Tudor domains, we next asked whether TPX2 interferes with 
53BP1 localization to DSBs. We depleted TPX2 from U2OS cells 
using shRNAs and analyzed 53BP1 irradiation-induced foci by 
immunofluorescence (Figs. 2 A and S1 D). 53BP1 foci were largely 
unaffected by loss of TPX2. Similarly, TPX2 loss did not have a 
significant effect on Rif1 foci formation, suggesting that TPX2 
does not contribute to the recruitment of 53BP1 or its effectors 
(Figs. 2 A and S1 E).
Since 53BP1 protects DNA ends from resection and subse-
quent repair by HR, we used flow cytometry to measure chro-
matin-bound RPA levels in S/G2 cells as a proxy for DNA end 
resection. Strikingly, we saw a considerable decrease in RPA 
binding in response to TPX2 loss after damage with camptoth-
ecin (Figs. 2 B and S1 F). To functionally assess HR, we used the 
DR-GFP reporter system and found that loss of TPX2 reduces 
HR efficiency (Fig. 2 C). Seeing that BRCA1 facilitates DNA end 
resection and HR, we used immunofluorescence to visualize 
BRCA1 foci following depletion of TPX2 or Aurora A. Remarkably, 
knockdown of either protein resulted in a significant decrease 
in BRCA1 irradiation-induced foci (Figs. 2, D and E; and S1 D). 
While TPX2- or Aurora A–depleted cells did exhibit a reduction 
in S/G2 phase compared with control cells, it was not sufficient to 
explain the magnitude of BRCA1 foci loss (Fig. S1 G). Additionally, 
using a U2OS-FUC CI cell cycle indicator cell line (Sakaue-Sawano 
et al., 2008), we found that TPX2 or Aurora A depletion decreased 
BRCA1 foci formation in S/G2 cells, further suggesting that cell 
cycle defects alone could not explain this phenotype (Figs. 2 F and 
S1 H). The loss of BRCA1 foci in TPX2-depleted cells could also be 
rescued by reexpression of TPX2 (Fig. S1, I and J). Furthermore, 
BRCA1 promotes HR by initiating Rad51 recruitment, and con-
sistently, knockdown of TPX2 or Aurora A resulted in decreased 
Rad51 foci (Fig. 2, G and H; Prakash et al., 2015). Together, our 
data suggest that TPX2 regulates BRCA1 recruitment to sites of 
DSBs as well as its role in repair by HR.
In addition to its function in end resection, BRCA1 has been 
shown to protect stalled replication forks from degradation by 
MRE11 upon replication stress induction (Schlacher et al., 2012). 
Therefore, we investigated whether TPX2 and Aurora A are also 
needed to carry out this additional function via genome-wide 
single-molecule DNA fiber analysis. TPX2- or Aurora A–depleted 
U2OS cells were labeled with the first thymidine analogue 
5-iodo-2′-deoxyuridine (IdU; red) followed by treatment with 
hydroxyurea (HU) and concomitant labeling with the second 
thymidine analogue, 5-chloro-2′-deoxyuridine (CldU; green). 
Shortening of the IdU (red) tract was measured as a readout 
of degradation, as described (Lemaçon et al., 2017). Control, 
TPX2-depleted, and Aurora A–depleted cells produced nearly 
identical IdU-labeled DNA track lengths in the absence of HU, 
indicating that replication fork speed was unaffected (Fig. S2 
A). Notably, when treated with HU, the IdU tracks of both the 
TPX2-depleted and Aurora A–depleted cells were significantly 
shorter compared with control cells (Fig. 3, A and B). Further-
more, this track-shortening phenotype was rescued upon the ad-
dition of Mirin, an MRE11-specific inhibitor. Track shortening 
due to TPX2 depletion could also be rescued by exogenous TPX2 
expression (Fig. 3 C). Strikingly, replication fork stability was not 
rescued by a catalytically inactive Aurora A (D274N; Bayliss et al., 
2003), nor was it rescued by an Aurora A mutant that does not 
interact with TPX2 (S155R; Bibby et al., 2009; Figs. 3 D and S2, B 
and C). These data suggest that Aurora A kinase activity as well 
as its interaction with TPX2 are critical for its role in replication 
fork stability.
Like BRCA1, TPX2 and Aurora A appear to play a critical role 
in preventing extensive MRE11-mediated degradation of stalled 
replication intermediates. Consistent with this, we found that 
TPX2 and Aurora A are present at nascent DNA using the accel-
erated native isolation of proteins on nascent DNA (aniPOND) 
assay (Fig. 3 E; Leung et al., 2013). Importantly, a thymidine chase 
reduced the abundance of these proteins on nascent DNA, sug-
gesting that they are associated with the replication fork.
As TPX2/Aurora A loss impairs DNA-end resection and 
BRCA1 foci formation and also compromises replication fork 
stability, we next asked whether TPX2 and BRCA1 function in a 
common fork protection pathway. We depleted TPX2 from both 
BRCA1-deficient UWB1 cells and from UWB1 cells complemented 
with BRCA1 (UWB1 + BRCA1) and performed DNA fiber analysis 
(Figs. 3 F and S2, D and E). As expected, in the presence of HU, 
BRCA1-deficient UWB1 cells produced significantly shorter IdU 
track lengths in comparison to the UWB1 + BRCA1 cells. Com-
parably shortened tracks were also observed upon HU treat-
ment in TPX2-depleted UWB1 + BRCA1 cells (Fig. 3 F). However, 
TPX2-depleted UWB1 cells produced even shorter IdU tracks than 
cells deficient for either BRCA1 or TPX2 alone, suggesting that 
TPX2 and BRCA1 function in separate pathways to protect stalled 
forks. These phenotypes were also observed in BRCA-deficient 
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Figure 1. Identification of TPX2/Aurora A as 53BP1 effectors. (A) Flag-HA-53BP1 and associated proteins were isolated from HeLa-S nuclear extract using 
sequential Flag and HA immunoaffinity purification. The final eluted material was analyzed by SDS-PAGE and silver staining. (B) The 53BP1 complex from A 
was analyzed by MS/MS twice, and the total/unique peptide numbers for each protein are shown for each run. (C) Nuclear extracts from HeLa-S cells were 
immunoprecipitated with control IgG or TPX2 antibody and Western blotted as shown. (D) GST, or the indicated GST-53BP1 fragments, were immobilized 
on glutathione-Sepharose, and binding with full-length recombinant His-TPX2 was tested. Bound material was analyzed by Western blot or Coomassie Blue 
staining. (E) Schematic of 53BP1 and summary of TPX2 binding data. (F) GST, GST-TPX2, or the indicated GST-TPX2 fragments were immobilized on glutathi-
one-Sepharose and assessed for binding to full-length Flag-53BP1, as in D. (G) Schematic of TPX2 and summary of 53BP1 binding data. (H) GST, and increasing 
equimolar amounts of GST-TPX2 or GST- TPX2-Δ150-394, were tested for 53BP1 binding as done in F. (I) Recombinant His-Aurora A was immobilized on Ni-NTA 
and incubated with GST, GST-TPX2, or GST- TPX2-Δ150-394. Bound material was washed, subsequently incubated with Flag-53BP1, washed again, and analyzed 
for binding by Western blot or Coomassie Blue staining.
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Figure 2. TPX2 and Aurora A regulate BRCA1 recruitment and function. (A) U2OS cells expressing the indicated shRNAs were irradiated (5 Gy) and ana-
lyzed for 53BP1 and pH2A.X foci formation. Percentage of cells with ≥10 53BP1 foci ± SD is shown on the right. Scale bar, 10 µm. Foci were quantitated from 
three biological replicates with n ≥ 200 cells per experiment. Statistics: Student’s two-tailed t test; *, P < 0.05. (B) U2OS cells expressing the indicated shRNAs 
were treated with camptothecin (CPT) as shown, and chromatin-bound RPA was quantified by flow cytometry. Bar graph indicates the percentage of S/G2 
cells that are RPA positive, as determined by 7-AAD staining from four biological replicates. Error bars represent ± SD. Statistics: Student’s two-tailed t test; *, 
P < 0.05. (C) Quantitation of HR efficiency of DR-GFP U2OS cells treated with the indicated shRNA and with or without the Flag-ISce expression vector. Cells 
were analyzed for GFP positivity via flow cytometry in three biological replicates as described in Materials and methods. Error bars indicate ± SD. Statistics: 
Student’s two-tailed t test; *, P < 0.05. (D and E) U2OS cells expressing the indicated shRNAs were irradiated (5 Gy) and analyzed for BRCA1 and p.H2A.X foci 
formation. Percentage of cells with ≥10 BRCA1 foci ± SD is shown on the right. Scale bar, 10 µm. Foci were quantitated from three biological replicates with n 
≥ 250 cells per experiment. Statistics: Student’s two-tailed t test; *, P < 0.05. (F) Schematic of FUC CI cell cycle indicator expression pattern of mK02-Cdt (red; 
G1) and mAG-Geminin (green; S/G2/M; left). U2OS-FUC CI cells were treated with the indicated shRNAs, and S/G2-phase cells (yellow or green cells; indicated 
by white arrows) were analyzed for BRCA1 foci formation (right). Percentage of S/G2 cells with ≥10 BRCA1 foci ± SD is shown on the right. Scale bar, 10 µm. 
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HCC 1937 cells, confirming that the observed effect is not cell type 
specific (Fig. S2, F and G).
Due to the biochemical interaction between 53BP1 and TPX2, 
we next investigated how 53BP1 may impact TPX2/Aurora A 
function in DSB repair and replication fork stability. Strikingly, 
we found that 53BP1 deficiency prevented the loss of BRCA1 and 
Rad51 foci formation upon TPX2 knockdown (Figs. 4, A–D; and 
S2 H). In addition, our aniPOND analysis demonstrated that, like 
TPX2 and Aurora A, 53BP1 localizes to replication forks (Fig. 3 E). 
Thus, we tested whether concurrent loss of 53BP1 may also pre-
vent stalled replication fork degradation due to TPX2 depletion. 
Indeed, knockout of 53BP1 partially rescued IdU track shorten-
ing in TPX2-depleted U2OS cells, while a complete rescue was 
observed in mouse embryonic fibroblasts (MEFs; Figs. 4, E and 
F; and S2, H–J). The interaction between TPX2 and 53BP1 was 
apparently important for the function of TPX2 in replication 
fork stability, as TPX2-BP1-IM failed to rescue TPX2 fork degra-
dation (Figs. 4 G and S3, A and B). Importantly, this mutant form 
of TPX2 localized to mitotic spindles similar to WT TPX2 (Fig. 
S3 C). This supports the notion that its functions in mitosis are 
preserved, consistent with its ability to activate Aurora A kinase 
(Fig. S1 C). Furthermore, using aniPOND, we found that TPX2 
depletion caused a moderate increase in 53BP1 binding to newly 
replicated DNA, and this effect appeared augmented when cells 
were treated with HU to stall replication forks (Fig. S3 D). To-
gether, our data suggest that TPX2/Aurora A promote DSB repair 
and replication fork stability by negatively regulating 53BP1.
In contrast to TPX2 depletion, loss of 53BP1 failed to prevent 
IdU track shortening in BRCA1-depleted U2OS cells, consistent 
with previous reports (Fig. S3, E–G; Ray Chaudhuri et al., 2016). 
This further substantiates our finding that TPX2 and BRCA1 pro-
tect stalled replication forks via separate pathways. As a positive 
control for these experiments, we also depleted TPX2 and BRCA1 
from PTIP-knockout U2OS cells, as PTIP is required for MRE11 
localization at stalled replication forks. As expected, loss of PTIP 
restored IdU track length in both BRCA1- and TPX2-depleted 
U2OS cells (Figs. 4 E, S2 H, and S3, E–G).
Given our evidence that TPX2/Aurora A are important for 
replication fork stability, we tested whether loss of Aurora A in-
creased sensitivity to HU. Indeed, U2OS cells deficient for Au-
rora A were significantly more sensitive to HU (Figs. 4 H and S3 
H). Strikingly, loss of 53BP1 significantly reduced HU sensitivity 
upon Aurora A depletion (Fig. 4 H). Thus, our data demonstrate 
that the functions of TPX2/Aurora A in maintaining replication 
fork stability depend on 53BP1.
This work uncovers a previously unappreciated function of 
TPX2 and Aurora A in promoting DNA end resection at DSBs and 
replication fork stability by negatively regulating 53BP1 function. 
We propose a model in which TPX2/Aurora A regulate DSB repair 
and replication fork stability via two distinct mechanisms that 
are both dependent on 53BP1 (Fig. 5). TPX2/Aurora A appear to 
regulate 53BP1 function during DSB repair, preventing BRCA1 
antagonism and thus allowing for DNA end resection and HR 
to take place (Fig. 5 A). This is reminiscent of the TIRR protein, 
which similarly antagonizes 53BP1 by binding to its Tudor do-
mains (Drané et al., 2017; Dai et al., 2018). In the context of rep-
lication stress, TPX2/Aurora A promote the protection of stalled 
replication intermediates from extensive degradation by MRE11, 
again by inhibiting 53BP1, through a mechanism dependent on 
Aurora A kinase activity (Fig. 5 B). Therefore, our model suggests 
a novel role for 53BP1 in counteracting replication fork stability, 
but in a manner that is distinct from BRCA1. Finally, our model 
provides a rationale for targeting Aurora A kinase for improved 
chemosensitization, particularly in BRCA1-deficient tumors.
Materials and methods
Cell culture
U2OS, HeLa, HeLa-S, 293T cells, and MEFs were cultured in 
DMEM (Invitrogen), supplemented with 10% FBS (Atlanta Bio-
logicals) and 100 U/ml penicillin-streptomycin (Gibco) at 37°C 
and 5% CO2. BRCA1 mutant ovarian cancer cell line UWB1.289 
(UWB1) and its complemented derivative expressing WT BRCA1 
(UWB1 + BRCA1; DelloRusso et al., 2007) cells were grown in 50% 
RPMI medium, 50% mammary epithelial cell growth medium 
bullet kit (Lonza CC-3150) completed with 3% FBS, 100 U/ml pen-
icillin, and 100 µg/ml streptomycin at 37°C in 5% CO2. Human 
triple-negative breast cancer cells HCC 1937 (Tassone et al., 2003, 
2005) were cultured in RPMI complemented with 10% FBS, 100 
U/ml penicillin, and 100 µg/ml streptomycin at 37°C in 5% CO2. 
Sf9 cells were grown in suspension in Sf-900 II serum-free me-
dium (Gibco), supplemented with 100 U/ml penicillin-strepto-
mycin (Gibco) at 27°C.
Plasmids
53BP1 and TPX2 cDNAs were isolated from total human RNA and 
cloned into pOZ-Flag-HA, pENTR-3C, or pENTR4. I-SceI cDNA (a 
kind gift from Maria Jasin, Sloan Kettering Institute, New York, 
NY) was subcloned into pENTR-3C by PCR. For mammalian 
cell expression, cDNAs were subcloned into pHAGE-CMV-Flag, 
pMSCV-Flag-HA, or untagged pMSCV as needed by Gateway re-
combination (Sowa et al., 2009). For expression in insect cells, 
53BP1 cDNA was subcloned into pDEST-BB-Flag by Gateway re-
combination. For bacterial expression, cDNAs were subcloned 
by PCR into pGEX-4T1 or pET-28a-Flag. All constructs derived by 
PCR, including deletions and point mutations, were confirmed 
by Sanger sequencing.
Transfection, virus production, and transduction
Retrovirus (pMSCV vectors) and lentivirus (pHAGE or pLKO.1 
vectors) were produced by cotransfection of 293T with the ap-
propriate packaging vectors (retrovirus: pVSV-G and pGag-Pol; 
lentivirus: pHDM-VSV-G, pHDM-tat1b, pHDM-Hg-PM2, and 
pRC-CMV-RaII; Mulligan et al., 2008). Viral supernatant was col-
Foci were quantitated from three biological replicates with n ≥ 250 cells per experiment. Statistics: Student’s two-tailed t test; *, P < 0.05. (G and H) U2OS cells 
expressing the indicated shRNAs were irradiated (5 Gy) and analyzed for Rad51 foci. Percentage of cells with four or greater Rad51 foci ± SD is shown on the right. 
Scale bar, 10 µm. Foci were quantitated from three biological replicates with n ≥ 250 cells per experiment. Statistics: Student’s two-tailed t test; *, P < 0.05.
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lected after 48–72 h and sterile filtered with a 0.45-µm filter. The 
indicated cell lines were then incubated with the viral superna-
tant and 4 µg/ml polybrene. For knockdown of TPX2, Aurora A, 
and BRCA1, cells were infected with the lentiviral shRNA vector 
60–64 h before analysis by immunofluorescence, flow cytome-
try, or fiber assay. Lentiviral shRNA vectors were obtained from 
Figure 3. TPX2 and Aurora A promote replication fork stability. (A) Representative DNA fiber images of control, TPX2-depleted, and Aurora A–depleted 
U2OS cells treated with HU (4 mM) for 120 min. IdU, red; CldU, green. Scale bar, 50 µm. (B) Schematic of single-molecule DNA fiber track analysis (top) and 
size distribution of IdU track length in TPX2- and Aurora A–depleted cells in the presence and absence of HU or Mirin (bottom). Mirin (50 µM) was added con-
comitantly with HU treatment, as indicated. Out of two biological replicates; n ≥ 300 tracks were scored for each dataset. Bars represent median. Statistics: 
Mann–Whitney; ****, P < 0.0001; n.s., not significant. (C) Labeling and HU treatment schematic (top) and size distribution of IdU track length in U2OS cells 
expressing the indicated combination of shRNA and TPX2 expression vector as performed in B (bottom). (D) Size distribution of IdU track length in U2OS cells 
expressing the indicated combination of shRNA and Aurora A expression vector as performed in B. (E) U2OS cells were pulse labeled with 10 µM EdU and 
subjected to a 1-h thymidine chase (10 µM). Proteins bound to nascent DNA were purified by aniPOND as described in Materials and methods and analyzed 
by Western blot. (F) Size distribution of IdU track length in BRCA1-deficient (UWB1) and -proficient (UWB1 + BRCA1) cells in the presence of HU. Cells were 
infected with control or TPX2 shRNA before IdU and CldU labeling, as indicated. Fiber analysis was performed as in B.
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Figure 4. TPX2/Aurora A negatively regulate 53BP1 in the DNA damage response. (A) WT U2OS or 53BP1 knockout cells expressing the indicated shRNAs 
were irradiated (5 Gy) and analyzed for BRCA1 and pH2A.X foci formation. (B) U2OS cells treated as in A were also analyzed by Rad51 and pH2A.X foci. Scale 
bars, 10 µm. (C) Quantitation of BRCA1 foci from A. Foci were quantitated from three biological replicates with n ≥ 200 cells per experiment. Error bars indicate 
±SD. Statistics: Student’s two-tailed t test; *, P < 0.05. (D) Quantitation of Rad51 foci from B. Foci were quantitated from three technical replicates with n ≥ 
200 cells per experiment. Error bars indicate ±SD. Statistics: Student’s two-tailed t test; *, P < 0.05. (E) Size distribution of IdU track length in U2OS cells. WT, 
53BP1 KO, or PTIP KO cells were treated with control or TPX2 shRNA before IdU and CldU labeling, as indicated. Out of two biological replicates; n ≥ 300 tracks 
scored for each dataset. Bars represent median. Statistics: Mann–Whitney; ****, P < 0.0001; n.s., not significant. (F) Size distribution of IdU track length in MEFs. 
WT or 53BP1−/− cells were treated with control or TPX2 shRNA before labeling and HU treatment as indicated. Fiber analysis was performed as in E. (G) Size 
distribution of IdU track length in U2OS cells expressing the indicated combination of shRNA and TPX2 expression vector. Out of three biological replicates; n ≥ 
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Sigma (control shRNA: SHC002) and GE Dharmacon (clone Id: 
TPX2-1, TRCN0000074533, 5′-TTA AAG GAA GTA ACT ACA TGG-3′ 
(antisense); TPX2-2, TRCN0000074536, 5′-AAG ATT AGC CTT TCT 
CAA AGG-3′ (antisense); TPX2-1 (mouse), TRCN0000120812, 5′-
AAA TAA CTA CAA GAA GTC TGG-3′ (antisense); TPX2-2 (mouse), 
TRCN0000120813, 5′-AAT TCT AGG ATC AAG TTC CCG-3′ (an-
tisense); Aurora A-1, TRCN0000000655, 5′-TAT AAG TAG CAC 
AAT TCT CGT-3′ (antisense); Aurora A-2, TRCN0000000656, 
5′-TTC GAA TGA CAG TAA GAC AGG-3′ (antisense); and BRCA1, 
TRCN0000009823, 5′-ATT CAT GCC AGA GGT CTT ATA-3′ (antisense). 
TPX2-1 and Aurora A-1 shRNAs were used for experiments in 
which only one knockdown is shown. For TPX2 and Aurora A 
rescue experiments, cells were infected with the pMSCV-TPX2 
retroviral vector and selected with blasticidin (10 µg/ml) for 72 h 
before shRNA infection.
Antibodies
All antibodies used in this study are listed in Table S2.
Purification of TAP-53BP1 complex and MS/MS analysis
Purification of 53BP1 was performed using an established tan-
dem immunoaffinity method (Nakatani and Ogryzko, 2003). 
Flag-HA-53BP1 was stably expressed after transduction of pOZ-
Flag-HA-53BP1 retrovirus into HeLa-S cells. Cells were harvested 
and resuspended in a 5× volume of hypotonic buffer (10 mM Tris, 
pH 7.3, 10 mM KCl, 1.5 mM MgCl2, 0.2 mM PMSF, 10 mM β-mer-
captoethanol, and protease inhibitors; Pierce). Cells were pelleted 
by spinning at 2,500 rpm, resuspended in 1× pellet volume of hy-
potonic buffer, and homogenized using a Dounce tissue grinder 
(Wheaton). Nuclear material was pelleted, resuspended in 0.5× 
pellet volume of low-salt buffer (20 mM Tris, pH 7.3, 20 mM KCl, 
1.5 mM MgCl2, 0.2 mM EDTA, 25% glycerol, 0.2 mM PMSF, 10 mM 
β-mercaptoethanol, and protease inhibitors), and Dounced 
again. 0.5× pellet volume of high-salt buffer (20 mM Tris, pH 7.3, 
1.2M KCl, 1.5 mM MgCl2, 0.2 mM EDTA, 25% glycerol, 0.2 mM 
PMSF, 10 mM β-mercaptoethanol, and protease inhibitors) was 
slowly added to nuclear extract, which was subsequently stirred 
for 30–45 min. Extract was spun down at 14,000 rpm for 30 min, 
and the soluble material was dialyzed in BC100 buffer (20 mM 
Tris, pH 7.3, 100 mM KCl, 0.2 mM EDTA, 20% glycerol, 0.2 mM 
PMSF, and 1 mM β-mercaptoethanol).
53BP1 complex was purified from the nuclear extract using an-
ti-Flag (M2) resin (Sigma), followed by purification using anti-HA 
(F-7) resin (Santa Cruz) in TAP buffer (50 mM Tris-HCl, pH 7.9, 
100 mM KCl, 5 mM MgCl2, 10% glycerol, 0.1% NP-40, 1 mM DTT, and 
protease inhibitors). For both Flag and HA purifications, nuclear 
extract was rotated with resin for 4 h, washed extensively with 
TAP buffer, and eluted with 0.4 mg/ml Flag or HA peptide (Sigma). 
After elution, the complex was TCA precipitated, and associated 
proteins were identified by liquid chromatography-MS/MS using 
an LTQ Orbitrap Velos Pro ion-trap mass spectrometer (Thermo 
Fisher Scientific) and Sequest software (Sowa et al., 2009).
Endogenous immunoprecipitation
HeLa-S cells were mock treated or irradiated (5 Gy) using an XCE 
LL 50 x-ray (Kubtec), and nuclear extract was prepared following 
a 1-h recovery period at 37°C as described above (Nakatani and 
Ogryzko, 2003). The nuclear extract was precleared with protein 
A/G-agarose (Santa Cruz) and then incubated overnight at 4°C 
with 3 µg antibody. The extract was then incubated with fresh 
protein A/G-agarose for 1 h at 4°C, centrifuged, and washed five 
times with TAP buffer. Bound material was eluted using Laemmli 
buffer and analyzed by Western blotting.
Recombinant protein purification
Recombinant GST-tagged TPX2 proteins were purified from 
Rosetta (DE3) using an ÄKTA-pure FPLC (GE Healthcare). Cells 
were resuspended in GST-lysis buffer (50 mM Tris-HCl, pH 7.3, 
250 mM NaCl, 0.05% Triton X-100, 3 mM β-ME 20, and pro-
tease inhibitors) and lysed by sonication. After centrifugation 
and filtration, the extract was loaded onto a GSTrap HP col-
umn (GE Healthcare). After washing with 20 column volumes 
of lysis buffer, the protein was eluted using lysis buffer con-
taining 10 mM glutathione. The eluted proteins were dialyzed 
into TAP buffer.
Flag-53BP1 was purified from Sf9 cells infected with pDEST-
BB-Flag-53BP1 recombinant baculovirus. Cells were resuspended 
in lysis buffer (20 mM Tris, pH 7.3, 150 mM NaCl, 8% glycerol, 
0.2% NP-40, 0.1% Triton X-100, 2 mM βME, and protease inhibi-
tors) and sonicated to complete lysis. After centrifugation, the cell 
extract was incubated with anti-Flag (M2) beads (Sigma) for 3 h. 
The bound material was eluted using lysis buffer containing 0.4 
mg/ml Flag peptide (Sigma) and dialyzed into TAP wash buffer.
GST-tagged protein pull-down assays
All binding assays were performed in TAP buffer with 1% BSA 
in a total volume of 100 µl, using 10 µl glutathione-Sepharose 
beads (GE Healthcare) per reaction. The beads were preblocked 
with 3% BSA in TAP buffer. Each reaction contained ∼5 µg GST-
tagged protein and ∼250 ng Flag-53BP1. Binding reactions were 
incubated at 4°C for 1 h with rotation. Beads were then washed 
extensively in TAP buffer, and a final wash was performed with 
1× PBS. Bound material was eluted with SDS loading buffer, ana-
lyzed by SDS-PAGE, and stained with Coomassie Blue or Western 
blotted as indicated.
Aurora A kinase assay
His-Flag-Aurora A was incubated with GST, GST-TPX2, or GST-
TPX2-BP1-IM in TAP buffer for 30 min at 4°C with rotation. 
Recombinant human histone H3.1 (1 µg; NEB) and ATP (10 mM 
final concentration) were subsequently added to each reaction 
for a total volume of 30 µl. Kinase reactions were incubated at 
room temperature for 30 min and stopped with the addition of 
30 µl Laemmli buffer. Phospho-H3 (S10) levels were measured 
by Western blot.
300 tracks scored for each dataset. Bars represent median. Statistics: Mann–Whitney; ****, P < 0.0001; n.s., not significant. (H) U2OS WT or 53BP1-knockout 
cells were treated with the indicated shRNAs and subsequently treated with HU, as described in Materials and methods. Cell viability after 48 h of drug expo-
sure was measured by MTS assay. Graph is a representative of three biological replicate experiments. Error bars indicate ±SD with n = 5 technical replicates.
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AniPOND
aniPOND assays were performed as previously described with 
some modifications (Leung et al., 2013; Wiest and Tomkinson, 
2017). Cells were pulse labeled with 10  µM EdU in DMEM for 
15 min, washed with PBS, and then incubated in medium with 
10 µM thymidine for 1 h or with 4 mM HU for 2 h. Medium was re-
moved, and cells were immediately lysed and harvested with nu-
clei extraction buffer (20 mM Hepes, pH 7.2, 40 mM NaCl, 3 mM 
MgCl2, 300 mM sucrose, and 0.5% NP-40). Nuclei pellets were 
washed with PBS and then resuspended in click reaction mix 
(in order of addition: 25 mM biotin picolyl azide [Click Chem-
istry Tools], 10 mM (+)-sodium l-ascorbate, and 2 mM CuSO4) 
and rotated at 4°C for 1 h. Samples were then washed with PBS, 
and pellets were resuspended in 500 µl Buffer B1 (25 mM NaCl, 
2 mM EDTA, 50 mM Tris-HCl, pH 8.0, 1% NP-40, and protease 
inhibitors). Samples were rotated for 30 min at 4°C, spun down 
at maximum speed for 10 min at 4°C, resuspended again in 500 µl 
Buffer B1, and rotated for an additional 30 min at 4°C. Nuclei were 
again pelleted and resuspended in 500 µl Buffer B1. Samples were 
then sonicated using a Model 50 Sonic Dismembrator (Thermo 
Fisher Scientific) 12 × 10 s at 20 amplitude to solubilize DNA-
bound proteins. Samples were spun down at maximum speed 
for 10 min, and the supernatant was collected. 500 µl Buffer B2 
(150 mM NaCl, 2 mM EDTA, 50 mM Tris-HCl, pH 8.0, 0.5% NP-
40, and protease inhibitors) was added to the supernatant to 
bring the total sample size to ∼1 ml. Samples were rotated over-
night (16–20 h) with streptavidin-coated beads (Thermo Fisher 
Scientific). A chromatin input sample was collected immediately 
before streptavidin capture. Beads were washed extensively with 
Buffer B2 and boiled in Laemmli buffer to elute bound material. A 
small amount of material was then analyzed for H3 via Western 
blotting, and densitometry of the bands was performed using 
ImageJ (National Institutes of Health). Loading adjustments 
were made based on these measurements, and the proteins of 
interest were then run on an SDS-PAGE gel and analyzed by 
Western blotting.
CRI SPR/Cas9-mediated knockouts
U2OS knockout cells were created using CRI SPR/Cas9 genome 
editing at the Genome Engineering and iPSC Center at Wash-
ington University School of Medicine (St. Louis, MO). All clones 
used for this study were confirmed by deep sequencing. The 
53BP1 knockout clone was further confirmed by Western blot 
analysis. The guide RNA sequences used to generate the knock-
out cell line were as follows: 53BP1, 5′-GAT ACA GCT CAA CAC AGA 
CA-3′; and PTIP, 5′-ATT TCT TAT TGA GGG TTA GC-3′.
Immunofluorescence microscopy
U2OS cells were seeded onto microscope coverslips and irradiated 
using an XCE LL 50 x-ray (Kubtec). Cells were incubated for 1 or 
6 h at 37°C, as indicated, for recovery. The cells were extracted 
with 1× PBS containing 0.2% Triton X-100 and protease inhibi-
tors (Pierce) for 10 min on ice and fixed with 3.2% PFA in 1× PBS. 
The cells were then washed extensively with IF Wash Buffer (1× 
PBS, 0.5% NP-40, and 0.02% NaN3) and blocked with IF Blocking 
Buffer (IF Wash Buffer plus 10% FBS) for at least 30 min. Cells 
were incubated with primary antibodies diluted in IF Blocking 
Buffer for 1 h to overnight at 4°C. Primary antibodies used were 
as follows: mouse anti-53BP1 (1:1,000; BD Biosciences; 612522), 
rabbit anti-pH2AX (1:1,000; Abcam; 26350), rabbit anti-Rif1 
(1:1,000; Bethyl; A300-569A), mouse anti-BRCA1 (1:1,000; Santa 
Cruz; 6954), rabbit anti-Rad51 (1:1,000; Santa Cruz; 8349), and 
mouse anti-HA (1:1,000; BioLegend; 901501). Cells were stained 
with secondary antibodies (conjugated with 1:1,000 diluted 
Alexa Fluor 488, 594, or Pacific Blue; Invitrogen) and Hoechst 
33342 (Sigma) and mounted using Prolong Gold mounting me-
dium (Invitrogen). Epifluorescence microscopy was performed 
on an Olympus fluorescence microscope (BX-53) using an ApoN 
60×/1.49 NA, UPlanS-Apo 60×/1.35, or an UPlanS-Apo 100×/1.4 
oil-immersion lens with immersion oil from Millipore (104699). 
Images were obtained at room temperature using an Olympus 
XM10 monochrome camera and cellSens Dimension software. 
Raw images were exported into Adobe Photoshop, and for any 
adjustments in image contrast or brightness, the levels function 
was applied. For foci quantitation, at least 200 cells were ana-
lyzed in triplicate, and a Student’s two-tailed t test was used to 
determine statistical significance.
For laser microirradiation experiments, cells were cultured 
for 24 h before irradiation with 1 µM BrdU (Sigma; cat #B9285). 
UVA laser (50 mW) striping was conducted using an inverted 
microscope (Eclipse Ti; Nikon) with a Palm MicroBeam laser 
microdissection workstation. After irradiation, cells were incu-
bated at 37°C for 15 min, and then processed for immunofluo-
rescence as stated above. Primary antibodies used were rabbit 
anti-TPX2 (1:500, Bethyl; A300-429A) and mouse anti–Aurora A 
(1:200; Abcam; 13824).
Flow cytometry
All flow cytometry experiments were performed on a BD FAC 
SCalibur three-color flow cytometer and analyzed using FlowJo 
software. To measure chromatin-bound RPA, U2OS cells were 
treated with 1 µM camptothecin for 1 h before collection. Cells 
were washed with PBS + 2% FBS and fixed for 15 min in BD Cy-
tofix/Cytoperm (BD Biosciences) at room temperature. Cells 
were then washed with Perm/Wash buffer (BD Biosciences) and 
stained with rat anti-RPA (1:200; Cell Signaling, 2208S). Cells 
were washed and stained with Alexa Fluor 488 goat anti-rat sec-
ondary (1:1,000; Invitrogen, A11006). Cells were again washed 
with Perm/Wash buffer and resuspended in PBS + 2% FBS con-
taining 7-AAD for analysis (Forment et al., 2012). For quantifi-
Figure 5. TPX2/Aurora A regulate DSB repair and replication fork stabil-
ity via negative regulation of 53BP1. (A) Model of TPX2/Aurora A regulation 
of 53BP1 in response to double-strand breaks. (B) Model of TPX2/Aurora A 
function in response to replication stress. See text for details.
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cation of HR, U2OS-DR-GFP cells (a gift from Maria Jasin) were 
infected with lentiviral shRNAs and subsequently infected 24 h 
later with pHAGE-Flag-ISce-I. 72  h after ISceI infection, cells 
were collected and resuspended in PBS, and GFP+ cells were 
measured via flow cytometry. Both RPA and DR-GFP assays were 
performed in triplicate, and 30,000 events were measured per 
experiment. To obtain cell cycle profiles of TPX2- and Aurora 
A–depleted cells, cells were collected 64 h after shRNA infection 
and fixed in 70% ethanol at −20°C overnight. Cells were washed 
in PBS with 1% BSA, treated with 100 µg/ml RNase, and stained 
with 50 µg/ml propidium iodide (Sigma). 10,000 events were 
measured per experiment. A Student’s two-tailed t test was 
used to determine statistical significance for all flow cytome-
try experiments.
DNA fiber analysis
DNA fiber analysis was performed as described previously 
(Quinet et al., 2017). Briefly, asynchronously growing cells 
were labeled with two thymidine analogues: 20  µM IdU 
(Sigma) followed by 200 µM CldU (Sigma) for the indicated 
times according to the labeling scheme used. For untreated 
conditions, we labeled first with IdU for 20 min, followed by 
three washes with 1× PBS, and then CldU for an additional 20 
min. For the experiments with HU, cells were labeled first with 
IdU for 20 min, followed by three washes with 1× PBS, and then 
CldU plus 4 mM HU for an additional 2 h. After labeling, the 
cells were harvested and resuspended in PBS at 150,000 cells/
ml. Cells were lysed and spread on positively coated slides 
and stained according to the protocol previously described 
(Prakash et al., 2015). Images of the fibers were sequentially 
acquired (for double label) with LAS AF software using TCS 
SP5 confocal microscope (Leica). A 63×/1.4 oil-immersion ob-
jective was used. A minimum of 300 tracks were measured 
for each sample using ImageJ, and for the DNA track lengths, 
the pixel length values were converted into micrometers using 
the scale bars created by the microscope. Data were plotted on 
a scatter dot graph plot. DNA fiber experiments were done in 
biological duplicate unless stated otherwise in the figure leg-
end. Statistical significance was assessed using unpaired non-
parametric Mann–Whitney compared ranks t test. Differences 
in fiber length ≤15% are not considered significant. Additional 
information on the minimal number of tracts that should be 
measured for a reliable estimation of changes in fork speed 
within a given sample has been previously described (Técher 
et al., 2013; Thangavel et al., 2015).
MTS survival assay
Cells were treated with either control or Aurora A lentiviral 
shRNAs for 48 h and then seeded in 96-well plates at a concen-
tration of 5,000 cells per well. The following day, cells were 
treated with the indicated dose of HU and incubated at 37°C 
and 5% CO2 for an additional 48 h. At that time, the medium 
was replaced with fresh medium containing the CellTiter MTS 
reagent (Promega). Cell viability was assessed by measuring the 
absorbance of each well at 490 nM using an Epoch Microplate 
Spectrophotometer (BioTek). All MTS assays were performed 
in quintuplicate.
Online supplemental material
Table S1 shows the total and unique peptides for each identified 
protein in the MS analysis of Flag-HA-53BP1. Table S2 lists all an-
tibodies used in this study. Fig. S1 shows supporting data for Figs. 
1 and 2, which demonstrate that TPX2/Aurora A impair BRCA1 
foci formation and DNA end resection in S/G2 but do not localize 
to DSBs. Fig. S2 contains supporting data for Figs. 3 and 4, show-
ing that loss of TPX2/Aurora A results in replication fork depro-
tection but does not affect replication fork speed. Fig. S3 shows 
additional data for Fig. 4, demonstrating that TPX2/Aurora A pro-
tects stalled replication forks in a manner that is independent of 
its mitotic functions, but through a direct interaction with 53BP1.
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